Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 5/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316976 | 0.80 | JAK3 (0.50) | BTKJAK3DOT1LLCKAKT2 | |
| SCHEMBL1045812 | 0.80 | JAK3 (0.50) | BTKJAK3DOT1LLCKAKT2 | |
| SCHEMBL16144729 | 0.73 | JAK3 (0.49) | JAK3DOT1LJAK2JAK1 | |
| SCHEMBL20411169 | 0.69 | JAK3 (0.67) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL19011936 | 0.69 | JAK3 (0.70) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL20411181 | 0.69 | JAK3 (0.67) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL2021046 | 0.67 | JAK3 (0.71) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL2021330 | 0.67 | JAK3 (1.00) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL2021049 | 0.67 | JAK3 (0.71) | JAK3DOT1LLCKAKT2GSK3B | |
| SCHEMBL10079358 | 0.67 | JAK3 (1.00) | JAK3DOT1LLCKAKT2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |